Introduction {#Sec1}
============

Cardiovascular disease (CVD) is the leading cause of death in the US, accounting for over one-third of all deaths in 2007 \[[@CR1]\]. By the year 2030, it is projected that over 40% of the US population will have some form of CVD \[[@CR2]\]. Obesity, reported to affect 34% of the US adult population \[[@CR3]\], is a major risk factor for CVD that may exacerbate other known CVD risk factors, such as hypertension, dyslipidemia, and diabetes \[[@CR1], [@CR4]\]. Weight loss improves these risk factors \[[@CR5]--[@CR8]\] with the degree of improvement often commensurate with the degree of weight loss \[[@CR5], [@CR9]\]. Bariatric surgery complemented by lifestyle modification is associated with gradual and sustained weight loss and has become a viable weight management approach in select patients \[[@CR7], [@CR10]--[@CR12]\], with some guidelines including laparoscopic adjustable gastric banding (LAGB) for individuals with body mass index (BMI) ≥30 and 1 or more comorbidities of obesity \[[@CR10]\]. Although surgery-facilitated weight loss typically improves CVD risk factors \[[@CR7], [@CR13]\], the long-term clinical impact of the weight loss on CVD risk factors and on outcomes after bariatric surgery is not well described.

Cardiovascular disease risk algorithms, including those developed within the Framingham Heart Study (FHS) \[[@CR14]--[@CR16]\], may inform predicted clinical impact of obesity and weight loss. Framingham Risk Scores (FRS) for 10-year coronary heart disease (CHD) are greater with BMI \[[@CR17]\] and several studies have documented substantial reductions in 10-year CHD risk 1 year after bariatric surgery \[[@CR18]--[@CR22]\]; however, these studies have not included LAGB. Notably, significant reductions in FRS have not been observed following pharmacologic or lifestyle weight loss interventions \[[@CR23]\].

The authors examined whether weight loss in LAGB‐treated obese patients would be associated with meaningful reductions in 10‐ and 30-year Framingham CVD risk scores 12--15 months post‐LAGB in a large observational US healthcare database.

Methods {#Sec2}
=======

The analysis in this article is based on previously collected data and does not involve any new studies of human or animal subjects performed by any of the authors. This study utilized data from a national network of outpatient offices, the Medical Quality Improvement Consortium (MQIC), using the GE Centricity electronic medical records system. The MQIC database contains de-identified patient clinical information from a nationally representative patient population in the US. Patients in the MQIC database with LAGB procedure were selected based on the following: LAGB procedure between January 1 2005 and April 30 2010 (baseline); BMI ≥30 kg/m^2^ at baseline, aged 30--73 years, with 12--15 months of data available after baseline. Patients with CVD diagnoses before baseline were excluded. Baseline measures were taken at the closest visit prior to, but not more than 90 days before, LAGB procedure. Matched non-LAGB patients were selected for each LAGB patient based on the following: no history of weight reduction surgery; index date between January 1 2005 and April 30, 2010 (baseline); BMI ≥ 30 kg/m^2^ at baseline; aged 30--73 years; and with 12--15 months of data available after baseline. Both groups of patients were required to have two BMI measures 12--15 months apart, and their baseline date was the first of these two measures. LAGB and non-LAGB patients were propensity score matched (according to year of baseline date) on baseline BMI, age, and gender. Within each year, selected matching patients were only used for one LAGB patient. It is possible that a non-LAGB patient selected as a match for an LAGB patient one year could also be identified as a match for a different patient in a subsequent year. Estimated risk for developing general CVD (coronary death, myocardial infarction, coronary insufficiency, angina, stroke, transient ischemic attack, peripheral artery disease, and heart failure) in the subsequent 10 or 30 years was calculated by two of the following methods: using office-based non-laboratory values and using lipid values where available \[[@CR14], [@CR15]\]. The office-based FRS is estimated using the following variables: gender, age, systolic blood pressure (SBP), BMI, smoking status, antihypertensive treatment, and diabetes status, while the lipid-based FRS replaces BMI with total cholesterol (TC) and high-density lipoprotein (HDL) cholesterol.

Diabetes was defined by International Classification of Diseases, 9th Revision (ICD-9) diagnosis and use of hypoglycemic medications (measured at baseline and 12--15 months). Remissions were defined as cessation of hypoglycemic medications.

Statistical Analysis {#Sec3}
--------------------

Changes in components of the Framingham CVD risk algorithms (BMI, SBP, TC, HDL, and diabetes) were also assessed. Changes were evaluated using paired (within group) or independent sample (between group) *t* tests for continuous measures and using Chi square test of proportions for categorical variables. Changes in outcome measures at 1 year were calculated using an average of values between 12 and 15 months. In addition, changes in CVD risk factors and scores were evaluated for subgroups stratified by gender and baseline BMI.

In order to assess individual contributions to changes in risk scores among LAGB patients, variables were assessed using a stepwise regression model and F statistics were calculated. *P*-values \<0.05 were considered statistically significant. Data manipulation and statistical analyses were performed using SAS^®^ (version 9.2, SAS Institute, Cary, NC, USA).

Results {#Sec4}
=======

A sample of 2,186 patients aged 30--73 years, with BMI ≥30 kg/m^2^, with LAGB after 2005, and 12--15 months of follow-up was identified in the MQIC database. Of these, 647 LAGB patients also had BMI measures at follow-up. A matched comparison group of 4,295 patients without surgical weight loss intervention was also identified.

Baseline Measures {#Sec5}
-----------------

Patient characteristics and CVD risk factor distributions at baseline and follow-up are presented in Table [1](#Tab1){ref-type="table"}. At baseline, LAGB patients were more likely to have diabetes than comparison patients (15.5 and 8.4%, respectively), while SBP was similar in both groups. Using office-based measures, the estimated 10- and 30-year Framingham CVD risks were 10.8 and 44.34% for LAGB patients and 10.56 and 41.79% for comparison patients at baseline, respectively.Table 1Patient demographics, CVD risk factors, and scores at baseline and follow-up for patients with office-based measuresPatient demographicsLAGB patients *n* = 647Non-LAGB patients *n* = 4,295*P* value for difference at baselineAge years, mean (SD)45.66 (9.3)46.44 (10.7)0.08Gender, *n* (%) Female525 (81.1)3,548 (82.6)0.36 Male122 (18.9)747 (17.4)Race, *n* (%) White82 (12.7)2,170 (50.5)\<0.0001 Black24 (3.7)383 (8.9) Other8 (1.2)203 (4.7) Not determined533 (82.4)1,539 (35.8)Clinical measuresBaseline12--15 monthsBaseline12--15 months*P* value for difference at baseline/follow-upBMI kg/m^2^ mean (SD)42.7 (7.0)33.4 (7.3)^a^41.6 (7.1)41.0 (7.3)^a^0.0002/\<0.0001BMI category *n* (%) \<300 (0.0)229 (35.4)0 (0.0)131 (3.1)0.0001/\<0.0001 30 to \<3585 (13.1)185 (28.6)685 (16.0)687 (16.0) 35 to \<40149 (23.0)125 (19.3)1,253 (29.2)1,243 (28.9) 40+413 (63.8)108 (16.7)2,357 (54.9)2,234 (52.0)SBP, mm Hg mean (SD)129.8 (15.0)122.6 (14.9)^a^129.6 (16.2)128.8 (15.8)^b^0.78/\<0.0001Diabetes, *n* (%)100 (15.5)53 (8.2)^a^362 (8.4)437 (10.2)^b^\<0.0001/0.12Current smoking *n* (%)122 (18.9)126 (19.5)1,028 (23.9)998 (23.2)0.004/0.0310-year CVD risk, %^c^ (office-based)10.8 (10.6)7.6 (8.2)^a^10.56 (10.7)10.57 (10.7)0.59/\<0.000130-year CVD risk, %^c^ (office-based)44.34 (22.9)32.30 (20.2)^a^41.79 (22.6)41.92 (23.0)0.008/\<0.0001*BMI* body mass index, *CVD* cardiovascular disease, *LAGB* laparoscopic adjustable gastric banding, *SBP* systolic blood pressure, *SD* standard deviation^a^ *P* \< 0.0001 for within group change from baseline^b^ *P* \< 0.05 for within group change from baseline^c^CVD risk estimates absolute risk of CVD event over the subsequent 10 or 30 years

Changes in Measures at Follow-Up {#Sec6}
--------------------------------

At 12--15 months' follow-up, mean BMI decreased significantly in LAGB patients (−9.3 kg/m^2^, *P* \< 0.0001) and in comparison patients (−0.6 kg/m^2^, *P* \< 0.0001; Table [1](#Tab1){ref-type="table"}). In addition, there were significant reductions in SBP for both LAGB (*P* \< 0.0001) and comparison patients (*P* \< 0.05). At follow-up, the proportion of patients using anti-diabetic medications decreased in LAGB patients (*P* \< 0.0001) and increased in comparison group (*P* \< 0.01). Estimated 10- and 30-year CVD risk scores decreased significantly in LAGB patients (−3.2%, *P* \< 0.0001 and −12.04%, *P* \< 0.0001, respectively), but did not change significantly in comparison patients (+0.01%, *P* = 0.91 and +0.13%, *P* = 0.42, respectively).

Seventy-four LAGB and 319 comparison patients had lipid data at baseline and follow-up. The LAGB subset with lipid data were older (*P* = 0.05), more likely to be male (*P* = 0.01), and have diabetes (*P* = 0.02) than patients without lipid data. In addition to BMI and SBP improvements, significant reductions in TC and HDL cholesterol occurred in both LAGB and comparison patients. The proportion of LAGB patients using anti-diabetic medications at follow-up decreased (*P* = 0.08), whereas this proportion increased among comparison patients (*P* = 0.28). Using lipid-based measures, estimated 10- and 30-year CVD risk decreased significantly in LAGB (−4.1%, *P* \< 0.0001 and −11.55%, *P* \< 0.0001, respectively) and comparison patients (−1.0%, *P* = 0.005 and −1.87%, *P* = 0.002, respectively; Table [2](#Tab2){ref-type="table"}). Direct comparison of office-based and lipid-based estimated 10- and 30-year CVD risk in the group with lipid data indicated that office-based calculations tended to estimate risk higher than lipid-based calculations. Mean (SD) estimated 10-year CVD risk in the 74 LAGB patients with lipid data available was 15.2% (12.8) and 9.7% (6.9) using office-based and lipid-based calculations, respectively, at baseline (*t* = 3.2; *P* = 0.002) and 9.7% (9.1) and 5.6% (4.8), respectively, at follow-up (*t* = 3.4; *P* \< 0.001). Mean (SD) estimated 30-year CVD risk in the 74 LAGB patients with lipid data available was 54.3% (23.6) and 34.3% (15.0) for office- and lipid-based calculations, respectively, at baseline (*t* = 6.2; *P* \< 0.001) and 38.4% (24.0) and 22.73% (12.7), respectively, at follow-up (*t* = 4.9; *P* \< 0.001). At follow-up, consistent relative risk reductions (−29.6 and −42.3% for 10-year CVD risk, −27.1 and −33.7% for 30-year CVD risk) were observed for either office- or lipid-based calculations, respectively (Fig. [1](#Fig1){ref-type="fig"}).Table 2Patient demographics, CVD risk factors, and scores at baseline and follow-up for patients with lipid-based measuresPatient demographicsLAGB patients *n* = 74Non-LAGB patients *n* = 319*P* value for difference at baselineAge, years, mean (SD)47.85 (8.9)51.56 (9.9)0.003Gender, *n* (%) Female52 (70.3)242 (75.9)0.32 Male22 (29.7)77 (24.1)Race, *n* (%) White5 (6.8)146 (45.8)\<0.0001 Black1 (1.4)23 (7.2) Other1 (1.4)16 (5.0) Not determined67 (90.5)134 (42.0)Clinical measuresBaseline12--15 monthsBaseline12--15 months*P* value for difference at baseline/follow-upBMI, kg/m^2^, mean (SD)43.9 (6.2)32.9 (7.6)^a^42.8 (8.0)41.8 (7.7)^a^0.27/\<0.0001BMI category, *n* (%) \<300 (0.0)28 (37.8)0 (0.0)8 (2.5)0.08/\<0.0001 30 to \<355 (6.8)22 (29.7)45 (14.1)47 (14.7) 35 to \<4016 (21.6)9 (12.2)87 (27.3)96 (30.1) 40+53 (71.6)15 (20.3)187 (58.6)168 (52.7)SBP, mm Hg, mean (SD)131.3 (14.6)119.5 (14.6)^a^130.7 (16.1)129.8 (15.0)0.77/\<0.0001Total cholesterol, mg/dL, mean (SD)197.7 (43.9)177.1 (40.1)^b^192.8 (44.6)187.3 (42.6)^b^0.39/0.06HDL, mg/dL, mean (SD)48.1 (12.0)58.7 (14.4)^a^46.9 (12.7)48.0 (12.4)^b^0.46/\<0.0001Diabetes, *n* (%)19 (25.7)11 (14.9)64 (20.1)71 (22.23)0.29/0.16Current smoking, *n* (%)15 (20.3)17 (23.0)71 (22.3)66 (20.7)0.71/0.6610-year CVD risk, %^c^ (lipid-based)9.7 (6.9)5.6 (4.8)^a^10.9 (10.3)9.9 (8.2)^b^0.34/\<0.000130-year CVD risk, %^c^ (lipid-based)34.28 (15.0)22.73 (12.7)^a^36.13 (16.3)34.26 (14.7)^b^0.37/\<0.0001*BMI* body mass index, *CVD* cardiovascular disease, *HDL* high-density lipoprotein, *LAGB* laparoscopic adjustable gastric banding, *SBP* systolic blood pressure, *SD* standard deviation^a^ *P* \< 0.0001 for within group change from baseline^b^ *P* \< 0.05 for within group change from baseline^c^CVD risk estimates absolute risk of CVD event over the subsequent 10 or 30 yearsFig. 1Relative change in CVD risk factors, and estimated 10- and 30-year CVD risk at 12--15 months. *BMI* body mass index, *CVD* cardiovascular disease, *HDL* high-density lipoprotein, *LAGB* laparoscopic adjustable gastric banding, *SBP* systolic blood pressure. *Asterisk* estimated 10- and 30-year CVD risk calculated using office-based algorithms for all patients, and using lipid-based algorithms for patients with lab measures \[[@CR18], [@CR19]\]

Between group comparisons of estimated CVD risk changes indicated that LAGB patients experienced significantly greater improvements than non-LAGB patients in 10- and 30-year CVD risk for both office-based (*P* \< 0.0001) and lipid-based (*P* \< 0.001) assessments (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Change in estimated 10- and 30-year CVD risk at 12--15 months, LAGB versus non-LAGB patients. *CVD* cardiovascular disease, *LAGB* laparoscopic adjustable gastric banding. *P* values reported for difference between LAGB and non-LAGB patients. *Asterisk* estimated 10- and 30-year CVD risk calculated using office-based algorithms for all patients, and using lipid-based algorithms for patients with lab measures \[[@CR18], [@CR19]\]

Subgroup Analyses {#Sec7}
-----------------

Changes in CVD risk factors and scores were evaluated for subgroups stratified by gender and baseline BMI (Fig. [3](#Fig3){ref-type="fig"}). Reductions in risk factors and estimated CVD risk were consistently observed for all LAGB as compared with non-LAGB groups, with the exception of lipid-based estimated CVD risks for patients with BMI 30 to \<35 kg/m^2^ (*n* = 5) and BMI 35 to \<40 kg/m^2^ (*n* = 16), though insufficient sample sizes may have limited statistical power in these groups. Overall, males and those with baseline BMI ≥40 kg/m^2^ experienced the greatest absolute risk reductions.Fig. 3Change in estimated 10- and 30-year CVD risk at 12--15 months by gender and baseline BMI. *BMI* body mass index, *CVD* cardiovascular disease, *LAGB* laparoscopic adjustable gastric banding. \**P* \< 0.05 for changes from baseline between LAGB and non-LAGB groups; BMI was presented as kg/m^2^

Factors Driving Risk Reduction {#Sec8}
------------------------------

The main drivers of estimated 10-year CVD risk reduction among LAGB patients were baseline CVD risk (*F* = 478.6; *P* \< 0.0001), SBP (*F* = 182.4; *P* \< 0.0001), and BMI (*F* = 38.4; *P* \< 0.0001) for office-based measures analysis, and baseline CVD risk (*F* = 113.8; *P* \< 0.0001), TC (*F* = 22.5; *P* \< 0.0001), and HDL (*F* = 12.5; *P* = 0.0007) for lipid-based measures analysis. The main drivers of estimated 30-year CVD risk reduction were baseline CVD risk (*F* = 308.9; *P* \< 0.0001), BMI (*F* = 236.0; *P* \< 0.0001), and SBP (F = 116.0; *P* \< 0.0001) for office-based measures analysis, and TC (*F* = 69.6; *P* \< 0.0001), baseline CVD risk (*F* = 56.0; *P* \< 0.0001), and HDL (*F* = 23.2; *P* \< 0.0001) for lipid-based measures analysis.

Discussion {#Sec9}
==========

Cardiovascular diseases are among the most significant health consequences of obesity. In this analysis, without intervention, approximately 44% of obese patients who underwent the LAGB procedure would be predicted to experience CVD over the subsequent 30 years. These LAGB patients experienced both significant weight loss and improvements in CVD risk factors, including SBP, total and HDL cholesterol, and diabetes. One year after the LAGB procedure, patients reduced their estimated risk of developing CVD over the next 10--30 years by approximately one-third.

Improvements in estimated CVD risk among LAGB patients also were significantly greater than among matched patients who did not undergo LAGB. Modest improvements in some CVD risk factors were observed in comparison patients, including SBP and lipids, which might be attributed to lifestyle or pharmacologic interventions. However, the proportion of patients with diabetes increased in non-LAGB patients, which may have adversely impacted CVD risk scores in this group.

Multivariate risk prediction algorithms such as those developed within FHS allow clinicians to predict short- and long-term CVD risk for patients to help guide medical decision-making. The consistency of observed CVD risk reduction using lipid-based algorithms among the subset with lipid data strengthens results, as this algorithm was not based on changes in BMI. However, a limitation of the study was the small sample with lipid data available and it is noted that the predicted CVD risk was higher for the office-based algorithms.

These findings are substantiated by recent results from the Swedish Obese Subjects study, a prospective, non-randomized study of obese patients treated with either bariatric surgery (19% with banding) or non-surgical intervention with median follow-up of 14.7 years. Among bariatric surgery patients, risk of total and fatal CV events was reduced by 33 and 53%, respectively, as compared with control patients after adjusting for baseline conditions \[[@CR24]\]. In addition, a recent systematic review and meta-analysis of studies reporting long-term mortality in morbid obesity among bariatric surgery patients reported significant reduced overall mortality in three studies and borderline reduced CVD mortality among two studies reviewed for LAGB procedure \[[@CR25]\]. Previous studies have demonstrated an association between increasing BMI and both overall and CVD-specific mortality \[[@CR26]--[@CR28]\], and weight loss has been consistently demonstrated to improve CVD risk factors, including hypertension, type 2 diabetes, and dyslipidemia \[[@CR29]--[@CR33]\]. In addition to improving CVD risk factors for individuals with comorbidities at time of intervention, weight loss is also associated with reduced risk of developing type 2 diabetes (58--88% risk reduction) \[[@CR7], [@CR32]\], low HDL cholesterol (43--79% risk reduction) \[[@CR7]\], hypertension (45% risk reduction) \[[@CR9]\], hypertriglyceridemia (49--71% risk reduction) \[[@CR7]\], metabolic syndrome (41% risk reduction) \[[@CR30]\], and stroke (22% risk reduction) \[[@CR34]\].

Significant weight loss after bariatric surgery is accompanied by substantial reductions in CVD risk factors \[[@CR7]--[@CR9], [@CR35]\] and overall mortality \[[@CR7], [@CR36]\]. Previous studies following other bariatric surgical procedures have also demonstrated significant reductions in predicted risk of CHD using FRS \[[@CR19]\]. Obese patients who receive bariatric surgery experience an overall decrease in Framingham 10-year CHD risk score of 2.0--3.5 points \[[@CR20]--[@CR22]\]. In comparison, a study examining Framingham CVD risk following lifestyle and pharmacological intervention with orlistat did not report significant reduction in predicted CVD risk at 1 year of follow-up \[[@CR23]\]. The present report is distinguished from and adds to previous investigations in terms of three significant approaches: (1) use of general CVD algorithms (including stroke and peripheral artery disease) rather than the more limited CHD algorithm, (2) use of 30-year Framingham risk prediction algorithms that may approximate lifetime risk for a younger patient population, and (3) estimating risk after the LAGB procedure.

The strengths of this analysis include the observational setting that utilized a large database of patients that are likely to be representative of US patients undergoing LAGB. Patients studied in this report reflect the following typical characteristics of LAGB patients: they are primarily female \[[@CR37]\], aged in their mid-40s \[[@CR37], [@CR38]\], with mean BMI of \~43--45 kg/m^2^ \[[@CR38]--[@CR40]\]. An additional strength of the study was the availability of a matched comparator group of obese patients who did not undergo surgical weight loss intervention. While lack of a randomized controlled design could be criticized, the practical and ethical nature of such a design is questionable and the propensity matched design is considered a strength to try to ensure comparability between the groups. However, because the design was non-randomized, differences between LAGB and non-LAGB patients other than matched characteristics could have existed (such as the unequal distribution of diabetes at baseline) and influenced results, although within group changes would not have been affected by the non-randomized design. Other limitations of the study include lack of data on lifestyle changes or pharmacologic interventions beyond those used for hypertension and diabetes management. Non-LAGB patients were expected to receive non-surgical standard of care, including lifestyle and pharmacologic interventions. Also, requiring 12--15 months of follow-up may have introduced selection bias, as it was unclear whether these patients were similar to patients who did not have the required follow-up. Furthermore, adverse events due to the LAGB procedure were not included in the analysis. Framingham CVD risk scores have not been validated for measuring changes in CVD risk over time or specifically in obese populations; however, in the present analysis scores based on BMI versus lipid data indicate similar and consistent magnitude of risk reduction. In addition, patients older than 59 years were included and the estimation procedure for 30-year CVD risk algorithm was developed on a sample aged 20--59 years \[[@CR15]\].

The predicted risk reductions assume patients would maintain the weight loss and improvements in risk factors over time; however, without longer-term follow-up, the authors cannot confirm this would be the case. However, several studies have demonstrated long-term weight loss maintenance among LAGB treated patients 4--12 years after the procedure \[[@CR11], [@CR12]\].

Conclusion {#Sec10}
==========

In conclusion, data from a large US healthcare database show patients receiving LAGB to have significant weight loss, and reduced CVD risk factors and estimated CVD risk, supporting the effectiveness of the LAGB procedure as a potential approach for management of obesity. These results add to the evidence of the cardiovascular benefits of significant weight loss among obese individuals and the potential long-term clinical impact of the LAGB procedure as a therapeutic intervention for obesity. Larger and long-term studies are needed to further document whether effects of LAGB on weight loss and CVD risk factors translate into reduced CVD incidence.
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